Paul Tudor Jones’s Jasper Therapeutics JSPR Stock Holding History

Paul Tudor Jones’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$205K	–	2722
2021 Q3	$205K	Buy	+2,000	New	+$204K	﹤0.01%	2295

Other funds holding JSPR

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paul Tudor Jones's JSPR Position: Q4 2021 in Review

Paul Tudor Jones sold out of Jasper Therapeutics (JSPR) in Q4 2021, closing a stake of 2,000 shares — an estimated $205K sold.

Paul Tudor Jones first reported a position in JSPR in Q3 2021 and held it in 1 quarter. The position peaked at $205K in Q3 2021. 25 funds tracked by Wall St. Rank hold JSPR as of Q4 2021.

Paul Tudor Jones reported no remaining Jasper Therapeutics position as of Q4 2021 after selling out during the quarter.
Paul Tudor Jones sold 2,000 Jasper Therapeutics shares in Q4 2021, an estimated $205K.
Paul Tudor Jones first reported a position in Jasper Therapeutics in Q3 2021 and held it in 1 quarter.
Paul Tudor Jones's Jasper Therapeutics position peaked at $205K in Q3 2021.
25 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.